Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT03455582

Cognition Evolution and MRI Markers in PPMS Patients on 2 Years

Cognitive impairment is nowadays more and more recognized as an important feature of the multiple sclerosis (MS) disease. Cognitive disorders frequency in MS is estimated between 40 and 60%. Cognitive impairment affects quality of life and vocational status in MS patients.

Until recently, little information was available on the cognitive dysfunction and their evolution that occur in primary progressive multiple sclerosis (PPMS) as compared with relapsing-remitting MS (RRMS). In PPMS pathological studies have shown the importance of cortical demyelination and meningeal inflammation suggesting that the GM alteration could play a major role in the cognitive impairment in this phenotype. The cognitive evolution and the brain tissue alteration at the origin of these difficulties remain poorly understood in PPMS. The use of new techniques for morphological and functional MRI can study the contribution of diffuse White Matter (WM) alteration (probably through disconnexion of relevant network) and diffuse Grey matter (GM) alterations in the cerebral cortex and other structures (the hippocampi, the cerebellum, and the thalami) in cognitive impairment in PPMS patients and on their evolution.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Key information

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

PATIENTS

  • Male or female;
  • Age ≥ 18 years;
  • PPMS diagnosis according to McDonald 2010 criteria;
  • Disease duration ≤ 15 years;
  • Native French speaking;
  • Being affiliated to health insurance;
  • Willing to participate and to sign informed consent.

HEALTHY CONTROLS

  • Male or Female;
  • Age ≥ 18 years;
  • Native French speaking;
  • Being affiliated to health insurance;
  • Willing to participate and to sign informed consent.

Exclusion criteria

PATIENTS

  • previous history of other neurological disease;
  • psychiatric comorbidity including severe depression according to DSM-IV;
  • alcohol or other addiction to toxic;
  • disabling visual or motor problems preventing participation to neuropsychological assessments;
  • change of psychotropic drug since less than one month;
  • contra-indication to MRI (pacemakers, aneurysm clips, artificial heart valves, ear implants, metal fragments or foreign objects in the eyes, skin or body,claustrophobia or refusing MRI);
  • illiteracy, is unable to count or to read;
  • pregnant or breastfeeding women;
  • patient concerned by articles L 1121-5 to L 1121-8 (persons deprived of their liberty by a judicial or administrative decision, minors, persons of legal age who are the object of a legal protection measure or unable to express their consent).

HEALTHY CONTROLS

  • history of neurological disease;
  • family history of MS;
  • psychiatric comorbidity including severe depression according to DSM-IV;
  • alcohol or other toxic addiction;
  • psychotropic drugs; known cognitive complaint or neuropsychological affection;
  • prior neuropsychological testing with the same tests less than 6 months
  • contra-indication to MRI (pacemakers, aneurysm clips, artificial heart valves, ear implants, meta fragments or foreign objects in the eyes, skin or body, claustrophobia or refusing MRI);
  • illiteracy, is unable to count or to read;
  • pregnant or breastfeeding women;
  • person concerned by articles L 1121-5 to L 1121-8 (persons deprived of their liberty by a judicial or administrative decision, minors, persons of legal age who are the object of a legal protection measure or unable to express their consent).

Treatment and study plan

Clinical Assessment

Other

Expanded Disability Status Scale (EDSS), ambulation test and Multiple Sclerosis functional composite (MSFC). Medications will be recorded.

Ecological evaluation

Other

Virtual reality task and Actual reality

Neuropsychological evaluation

Other

cognitive tests exploring information processing speed, attention/concentration, working and episodic memories and executive function

Psychological evaluation

Other

questionnaires for depression, anxiety and fatigue

MRI Evaluation

Device

morphological MRI and resting state functional MRI (fMRI)

Primary outcomes

  1. Change of composite z cognitive score based on individual neuropsychological scores

    Time frame: At baseline (day 0) and at 24 months from baseline

    The composite z cognitive score is the average of z individual cognitive scores. The score from each cognitive test is transformed into z-scores. Z-scores will be calculated for each cognitive score with the following formula: (patient's score - mean value of HC group matched for age, sex, and education level)/standard deviation of the matched HC for each evaluation time (baseline and 2 years).

    Individual neuropsychological scores included in composite z cognitive score : the Alertness subtest, the divided attention subtest and the visual-scanning subtest from the TAP, The Symbol-digit-modalities-test, the Paced-Auditory-Serial-Addition-Test 3s, reversed span, the Stroop test, the Verbal fluency, Trail Making test, the California Verbal memory learning test and the Brief visual memory test -revised

Secondary outcomes

  1. Correlation of composite z cognitive score and ecological score with MRI parameters reflecting grey and white matter integrity and anatomic/functional connectivity

    Time frame: At baseline (day 0) and at 24 months from baseline

    The composite z cognitive score is the average of z individual cognitive scores. The score from each cognitive test is transformed into z-scores. Z-scores will be calculated for each cognitive score with the following formula: (patient's score - mean value of HC group matched for age, sex, and education level)/standard deviation of the matched HC for each evaluation time.

    The composite z ecological score is the average of z ecological scores of virtual reality task (Urban DailyCog©) and actual reality tests.

  2. Change of composite z cognitive score based on individual neuropsychological scores

    Time frame: At baseline (day 0), at 12 months and at 24 months from baseline

    The composite z cognitive score is the average of z individual cognitive scores. The score from each cognitive test is transformed into z-scores. Z-scores will be calculated for each cognitive score with the following formula: (patient's score - mean value of HC group matched for age, sex, and education level)/standard deviation of the matched HC for each evaluation time.

  3. Changes of composite z ecological score based on individual ecological scores

    Time frame: At baseline (day 0), at 12 months and at 24 months from baseline

    The composite z cognitive score is the average of z individual cognitive scores. The score from each cognitive test is transformed into z-scores. Z-scores will be calculated for each cognitive score with the following formula: (patient's score - mean value of HC group matched for age, sex, and education level)/standard deviation of the matched HC for each evaluation time. The composite z ecological score is the average of z ecological scores of virtual reality task (Urban DailyCog©) and actual reality tests.

Sponsors and collaborators

Lead sponsor

University Hospital, Bordeaux

Other

Collaborators

  • Roche Pharma AG

Registry information

Official study title

Longitudinal Study of Cognition in Primary Progressive Multiple Sclerosis: a Cohort Study

Acronym: PRO-COG

Important dates

Study start
2018
Primary completion
2026
Study completion
2026
First posted
Mar 6, 2018
Registry last updated
Feb 3, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.